Form 4: Acrivon CMO Granted 225,000 Stock Options

Acrivon Therapeutics' Chief Medical Officer, Mansoor Raza Mirza, was granted 225,000 stock options with an exercise price of $1.81, vesting over four years.

Summary

• Mansoor Raza Mirza, Chief Medical Officer of Acrivon Therapeutics, Inc. (ACRV), was granted 225,000 stock options.
• The transaction date for this grant was October 1, 2025.
• The exercise price for these stock options is $1.81 per share.
• The options will vest with 25% of the shares vesting on November 1, 2026, and the remaining shares vesting in 36 substantially equal monthly installments thereafter.
• Vesting is contingent upon the Reporting Person's continuous service through each vesting date.
• The expiration date for these stock options is September 30, 2035.
• Following this transaction, Mansoor Raza Mirza beneficially owns 225,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is generally a positive sign for executive alignment and retention, though it is a routine compensation disclosure.

Positives

• The grant of stock options aligns the Chief Medical Officer's financial interests with the long-term performance of Acrivon Therapeutics, Inc.
• This compensation structure can serve as a retention mechanism for key executive talent.

Future Outlook

The vesting schedule for the stock options, extending over four years, indicates an expectation of continued service from the Chief Medical Officer and aligns executive incentives with long-term company performance.

Industry Context

This stock option grant represents a standard executive compensation practice within the biotechnology and pharmaceutical industries, designed to attract, retain, and incentivize key management by aligning their financial interests with shareholder value creation over the long term.

Stakeholder Impact

• Shareholders: The grant aligns the Chief Medical Officer's interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: This compensation structure may signal stability in key leadership and a commitment to long-term incentives.

Next Steps

• The stock options will begin vesting on November 1, 2026, with subsequent monthly installments over 36 months, subject to continuous service.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, Stock Options, Insider Transaction, Executive Compensation, Form 4, Biotechnology, Chief Medical Officer